VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ISHL12 2022 | Updates on the diagnosis, risk stratification and management of HL

Stephen Ansell, MD, PhD, Mayo Clinic, Rochester, MN, discusses recent updates in the diagnosis and management of Hodgkin lymphoma (HL), and the need to improve methods of diagnosing uncommon subsets, such as nodular lymphocyte-predominant HL. Prof. Ansell also comments on the growing role of novel technologies and biomarkers in the risk stratification of patients with HL. This interview took place at the 12th International Symposium on Hodgkin Lymphoma (ISHL12), held in Cologne, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Research funding from Seattle Genetics, BMS, Affimed, Regeneron, Takeda, AstraZeneca, Pfizer, ADC Therapeutics to my institution for clinical trials.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter